Galderma acquires ZO Skin Health for $1.5B

Sophia Harris 10/15/2026

The world of dermatological skincare is buzzing with major shifts, and a monumental deal has just landed, signaling a massive expansion for Galderma. The global skincare giant has signed a landmark agreement to acquire the US physician-dispensed brand ZO Skin Health for a staggering US$1.5 billion, setting the stage for a powerful new era in medical aesthetics.

This acquisition is far more than just a transaction; it is a strategic masterstroke designed to deepen Galderma’s foothold in the rapidly evolving medical-grade skincare market. By bringing ZO Skin Health into its portfolio, Galderma is instantly strengthening its offering, especially as it expands its presence in the lucrative medical aesthetics sector.

ZO Skin Health, founded by renowned dermatologist Dr. Zein Obagi, has already carved out a significant niche. The company operates globally, managing a vast network of over 16,500 accounts spanning physician practices, medical spas, and online retailers across more than 40 countries. This extensive reach demonstrates the global demand for professional-grade, clinically-backed skincare solutions.

The financial scale of the operation is impressive. In the 12 months leading up to June 2026, ZO Skin Health generated approximately US$330 million in net sales, providing a solid foundation for the combined entity’s future growth.

The synergy between the two companies is poised to be transformative. The integration will complement Galderma’s existing powerhouse brands, such as Cetaphil and Alastin, creating an unparalleled range that bridges professional skincare with advanced aesthetic treatments.

This move positions Galderma perfectly to leverage its expertise in injectable aesthetics while expanding its capabilities in high-end, medical-grade dermatological care. The acquisition unlocks significant opportunities for international distribution, product innovation, and cross-category growth.

As the deal moves forward, Galderma plans to commit increased commercial investment to support the acquired brand’s future expansion. The transaction is currently expected to close in the fourth quarter of 2026 or early 2027, pending necessary regulatory approvals.

Ultimately, this deal is about more than just market share; it’s about redefining the intersection of science and beauty, promising a future where professional skincare and aesthetic treatments converge into an even more powerful and accessible experience for everyone.